ClinicalTrials.gg
TerminatedNCT05631431Updated Oct 26, 2026

Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Curalin in Type2 Diabetes, sponsored by CuraLife. Terminated at 4 sites in Israel. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CuraLife · Phase 2, Interventional, and Supportive care

How we know

Why this study was terminated
The study was stopped due to suspicion of a safety issue that was later found to be negligible

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.
Updated Oct 26, 2026Now TerminatedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel — 10 open to participants now, 16 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Israel.

Enrollment
136th of 197
135 · median 343
Started
2021
with 5 others
Phase 2
19 of 223
none open now
Registered
198th of 223
by date

Among the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, this one is the 136th largest by enrollment of the 197 interventional ones that give a count, is one of 6 that started in 2021, is one of 19 in phase 2, and was the 198th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, or all of them as a file.
02

Study summary

Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults with Type 2 Diabetes Mellitus

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Curalin As Add-On Therapy in Adults with Type 2 Diabetes Mellitus

03

Conditions studied

  • Type2 Diabetes

Browse trials for

Keywords

  • Diabetes
  • Type 2 Diabetes
  • placebo
  • Curalin
  • CuraLife
  • Momordica Charantia
  • Gymnema Sylvestre
  • Trigonella Foenum Graecum
  • Curcuma Longa
  • Emblica Officinalis
  • Swertia Chirata
  • Picrorhiza Kurroa
  • Syzygium Cumini/ Eugenia Jambolana
  • Cinnamomum Zeylanicum
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 135 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

CuraLife is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Diagnosis and Criteria for Inclusion:

Patients may be included in the study if they meet all of the following criteria:

  • Written is obtained.
  • Adult patients (18-85 years of age) with Type II diabetes mellitus
  • at screening is 7.5% - 10%
  • (BMI)>25
  • Stable body weight (±10%) within the 3 months preceding study entry

    • Patients were steadily treated with anti-diabetic medications, such as: GLP-1, Glucophage, DPP-4 inhibitor, or SGLT-2 inhibitor for at least 3 months or more prior to study entry
  • The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.

Criteria for Exclusion: Patients will be excluded from participating in this study if they meet 1 or more of the following criteria:

  • Patients who have been using Curalin At least once in the past 3 months
  • Persons with known sensitivity to any of the components of the Curalin product.
  • The patient has any uncontrolled medical condition (treated or untreated).
  • Patients with renal insufficiency ( [GFR]≤30 mL/min/1.73m2)
  • Pregnant or lactating women. Women of will be administered a urine pregnancy test at study entry. All study participants will confirm their willingness to use throughout the study.
  • Patients deemed by the Investigator as unable to complete study participation.
  • Patients currently treated with insulin or those that have been treated with insulin for more than 10 days in the 3 months prior to study entry.

    • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, local, dermal and inhaled , and or immunomodulating agents for more than a month prior to study entry, or during the study
  • The patient participated in a clinical study ( study drug or study device) within 30 days of the study entry
  • less than 1 year
  • History of stroke, , or myocardial infarction within six months prior to screening

    • Patients with uncontrolled hypertension defined as a systolic blood pressure ≥180 mmHg or a diastolic blood pressure ≥100mmHg.
    • Patients who have thyroid-stimulating hormone (TSH) levels >1.5 times the .
    • Patients with significant liver disease or liver function impairment defined as any of the following; cirrhosis, hepatitis, biliary obstruction with hyperbilirubinemia (total >2 times the upper limit of normal) and (AST) or alanine aminotransferase levels (ALT) >3 times the upper limit of normal.
    • Patients with creatine kinase concentrations > 10 times the upper limit of normal or creatine kinase elevation due to known muscle disease at visit 1 (screening 1)
  • Laboratory abnormalities at screening including:
  • Potassium > 5.5 mEq/L
  • Sodium under 130 mEq/L
  • under 10 g/dl for Women or Under 11 g/dl for man
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Dietary Supplement: Curalin

  • Active comparator
    Treatment

    Dietary Supplement: Curalin

Interventions

  • Dietary supplementCuralin

    Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals

07

What researchers measure

Primary outcomes

  1. primary objective

    The primary objective of this study is to evaluate the effect of treatment with Curalin on the change in plasma HbA1c.

    Time frame: 3-6 months

08

Study locations

4 sites
  • Soroka Medical Center
    Beersheba, Israel
  • Lin Medical Center
    Haifa, Israel
  • Herzelia Diebetes Center
    Herzliya, Israel
  • Ichilov Medical Center
    Tel Aviv, Israel
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Jun 2023, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Oct 2021 → Dec 2021 and primary completion May 2023 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Nov 30, 2022
StartActual
Dec 14, 2021was Oct 2021
Primary completionActual
Jun 29, 2023was May 2023
CompletionActual
Jun 29, 2023
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated The study was stopped due to suspicion of a safety issue that was later found to be negligible
changed Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • Soroka Medical Center · Beersheba, Israel
Show 1 removed
  • Soroka Medical Center · Be'er Sheva, Israel
Oct 26, 2026
Start date
Oct 15, 2021→Dec 14, 2021
Oct 26, 2026
Primary completion
May 15, 2023→Jun 29, 2023 (actual)
Oct 26, 2026
Study completion
Jun 30, 2023→Jun 29, 2023 (actual)
Oct 26, 2026
Enrollment
120 (estimated)→135 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Status unknown→Terminated
    Why stopped The study was stopped due to suspicion of a safety issue that was later found to be negligible
    1 site added, 1 site removed
    Show site
    • Soroka Medical Center · Beersheba, Israel
    Show 1 removed
    • Soroka Medical Center · Be'er Sheva, Israel
    Start date Oct 15, 2021→Dec 14, 2021
    Primary completion May 15, 2023→Jun 29, 2023 (now actual)
    Study completion Jun 30, 2023→Jun 29, 2023 (now actual)
    Enrollment 120 (estimated)→135 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05631431
Lead sponsor
CuraLife
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Dec 14, 2021
Primary completion
Jun 29, 2023
Completion
Jun 29, 2023
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion